Abstract | Survival rates for most paediatric cancers have improved at a remarkable pace over the past four decades. In developed countries, cure is now the probable outcome for most children and adolescents who are diagnosed with cancer: their 5-year survival rate approaches 80%. However, the vast majority of these cancer survivors will have at least one chronic health condition by 40 years of age. The burden of responsibility to understand the long-term morbidity and mortality that is associated with currently successful treatments must be borne by many, including the research and health care communities, survivor advocacy groups, and governmental and policy-making entities.
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, it is a distinct subgroup with respect to cancer type, biological features, response to treatment and long-term outcomes [2] [3] [4] [5] (FIG. 1) . It is estimated that in this subgroup there are approximately 13,500 new cases per year in the United States and the incidence has been increasing at an average rate of 0.5% per year since 1975 (REF. 1 ). Approximately 50% of childhood and adolescent cancers are acute leukaemia or cancers of the central nervous system. Included in the remaining cases are diagnoses such as retinoblastoma, neuroblastoma, Wilms' tumour and hepatoblastoma, which are primarily confined to the paediatric age range and occur almost exclusively in the first 5 years of life. For paediatric cancers, the highest age-specific incidence is within the first year of life.
Over the past 30 years, the survival rate in children and adolescents with cancer has steadily improved (FIG. 1) and the cancerspecific death rate has decreased by more than 50%. Nonetheless, cancer still remains the most common cause of disease-related mortality in this age group. Currently, eight of every ten children and adolescents who are diagnosed with cancer will survive ≥5 years beyond their diagnosis 1 . The overwhelming majority of those who reach the 5-year milestone will become long-term survivors 5 . The US National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER) programme estimates that, as of 1 January 2010, there were approximately 379,100 individuals living in the United States who had been diagnosed with cancer during childhood or adolescence 5 ; this can be compared with the estimate of 328,650 in 2005 (REF. 6 ). Assuming constant rates of incidence and survival post-2009, the prevalence of paediatric cancer survivors is predicted to surpass 420,000 by the end of 2013 and will approach 500,000 by 2020. We can currently estimate that approximately one of every 750 individuals in the United States is a survivor of childhood or adolescent cancer. This growing population reflects a highly vulnerable group of individuals who will probably experience adverse healthrelated and quality-of-life outcomes during their subsequent lifetimes, as a result of their curative cancer treatment [7] [8] [9] [10] [11] . Extended surveillance of childhood and adolescent cancer survivors has shown that they have a high risk of early mortality from subsequent cancers (that is, cancer other than that originally diagnosed), cardiac events and pulmonary conditions 12, 13 . This Science and Society article focuses on these adverse health-related and quality-of-life issues and discusses how these might be addressed by collaborative research.
Risk of adverse health outcomes
To varying degrees, long-term survivors of childhood cancer experience a range of adverse outcomes 12, [14] [15] [16] [17] [18] [19] (FIG. 2) . Although it is important to identify, quantify and characterize exposure-specific risks, a priority is to characterize those survivors at the highest risk and to target them for intervention-based strategies 20 . The aetiology and the associated morbidity of many adverse outcomes that are experienced by childhood cancer survivors may be multifactorial, involving combinations of factors after treatment 21 (FIG. 3) . Factors that relate to the primary malignancy, demographics, pre-morbid conditions, underlying genetic predisposition and health-related behaviours can modify the risks that are associated with treatment. Nonetheless, with the exception of specific conditions (such as mutations in relevant genes), it is typically treatment-specific factors that determine the risk of adverse late effects. Provided below are selected examples of treatment-specific adverse outcomes.
Radiation therapy. Radiation therapy has been an essential form of treatment for many childhood malignancies 22, 23 . With the increasing number of survivors and the longer follow-up duration, knowledge of the long-term adverse late effects that are associated with radiation therapy has greatly increased. There are several factors that can influence radiation-associated risks, including the radiation source, cumulative dose, volume and fractionation, as well as demographic factors such as sex and age at the time of radiation exposure 24 . Organ-specific radiation exposure affects the risk of organ-specific adverse outcomes, typically in a dose-dependent manner 25 . Radiation-associated outcomes include cardiovascular [26] [27] [28] [29] , cerebrovascular 30-32 , Nature Reviews | Cancer endocrine [33] [34] [35] [36] [37] [38] , gastrointestinal 39 , reproductive 15, [40] [41] [42] [43] [44] , hepatic 45 , pulmonary [46] [47] [48] [49] and urinary tract [50] [51] [52] dysfunction, musculoskeletal growth impairment [53] [54] [55] , and neurocognitive, neurosensory and neurological deficits [56] [57] [58] [59] [60] [61] (TABLE 1) . Cancer survivors whose treatment included radiation therapy are at risk of invasive and non-invasive secondary neoplasms [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] . Among childhood cancer survivors, risks have been well-described for cancers of the skin (predominantly basal cell carcinoma) 62, 63, 72, 73 , breast 69, 77, 78 , thyroid 64, 75, 79 , bone 68 and brain 70, 80, 81 . Increasingly, with extended follow-up from larger paediatric cancer cohorts, data are beginning to show radiation-associated risks for subsequent neoplasms that involve the colon and rectum 67, 71, 76 , the kidney 82 and the lung 83 .
Chemotherapy. Specific classes of chemotherapeutic agents that are used in the successful treatment of children and adolescents with cancer 22,23 -including alkylating agents 41, 42, 46, 51, 52, [84] [85] [86] [87] , anthracycline antibiotics 29, 88, 89 , antimetabolites 45, 51, 61, 90 , corticosteroids 60, 90, 91 , epipodophyllotoxins 86 and vinca alkaloids 92, 93 -are associated with a broad range of potential long-term late effects (TABLE 2) . The risk for adverse long-term outcomes that are associated with chemotherapy is generally dependent on the cumulative dose, but it might also depend on the scheduling and route of administration, as well as the sex and age of the patient. Beyond these factors, there remains considerable inter-individual variability in observed risk of therapyrelated late effects, which has been the focus of research that aims to characterize and quantify the potential contribution of genetic predisposition 94 .
Surgery. Surgical procedures that are carried out as part of the diagnosis or treatment of cancer in children and adolescents can have long-term effects on health status and quality of life 95 . Examples of long-term effects of surgery include amputation and limb-sparing procedures that can directly affect physical function and mobility 18, 96 ; eye enucleation, which affects craniofacial development 97 ; oophorectomy or orchiectomy, which affects reproduction 41, 42 ; cystectomy, which affects bladder function 52 ; nephrectomy, which subsequently affects renal function 51 ; splenectomy, which affects risk of infection 95 ; and neurosurgical procedures that can result in neurocognitive, neuroendocrine or motor sensory deficits and in seizures, as well as spinal cord injury that results in incontinence or sexual dysfunction 58, 98 . Beyond the functional implications of surgery, scarring and disfigurement can also affect the quality of life of survivors 99 .
Variable latency of late effects. Clinicians who supervise the care of childhood cancer survivors should be aware of the variable latency that is associated with clinical manifestation of cancer treatment toxicities, as well as patient and treatment factors that modify risk. Some treatment effects present soon after exposure and persist long term, whereas others develop many years after the completion of therapy. For example, the sensorineural hearing loss that is associated with cisplatin treatment typically develops soon after treatment (an acute toxicity) and persists during long-term follow-up 57 . Younger age at the time of treatment, higher cumulative dose and combined-modality therapy that includes ototoxic radiation, increase the risk and severity of the hearing deficit. An appreciation of the natural history of cisplatin-induced ototoxicity has resulted in the proactive monitoring of hearing during treatment and has facilitated timely preventive and remedial interventions to optimize language development and academic achievement among young cancer survivors. By contrast, young women who are treated with chest radiation for childhood cancer have an increased risk of breast cancer with a median time to diagnosis of 15-20 years after the radiation; breast cancer risk is increased as early as 8 years after radiation exposure 100 . The dose and the volume of breast tissue in the radiation treatment field are important modifiers of risk, as are other cancer treatments that may affect ovarian function. These data directly informed the recommendations for the initiation of breast cancer surveillance among young women who are treated with chest radiation for childhood cancer 100 .
Evaluating evolving therapy
Paediatric cancer treatment approaches have evolved over time in response to medical advances in cancer biology, developmental therapeutics, radiation technology, diagnostic imaging and supportive care. Surprisingly, despite the many changes that have been undertaken during the past 50 years in efforts to improve the outcomes among children with cancer, the specific drugs and treatment modalities that were used in early clinical trials are still included in contemporary treatment protocols 22, 23 . Initial paediatric-focused cancer therapy trials aimed to prevent developmental toxicities from affecting physical and intellectual growth and development. Subsequent progress in cancer biology and therapeutics has resulted in greater numbers of survivors living into adulthood and has facilitated the appreciation of the increased risk of organ dysfunction and secondary carcinogenesis in ageing survivors. These findings collectively stimulated a reassessment of the short-and long-term gains that are associated with the use of intensive multimodality therapy in young people, and this produced paradigm shifts in the management of many paediatric cancers. For example, cranial irradiation was once lauded for its effectiveness in treating and preventing central nervous system disease in children with acute lymphoblastic leukaemia, but its use in frontline treatment protocols is now limited 101 . In the case of paediatric Hodgkin's lymphoma treatment, doses of anthracyclines, as well as the fields and volumes of chest irradiation are proactively restricted to decrease the risk of both cardiovascular injury and the development of subsequent neoplasms -especially breast cancer among female survivors 102 . These and similar modifications that have been undertaken for other paediatric malignancies have reduced the occurrence of life-threatening complications that present during childhood and adolescence, but their effects on ageing adults have not been established. However, as outlined above, contemporary therapy is still associated with many life-altering toxicities that affect neurocognitive, neurosensory, endocrine and reproductive function [8] [9] [10] . Pre-emptive screening and surveillance of at-risk treatment groups can facilitate the early detection of and timely intervention for these common late effects. In general, the clinical course of normal tissue injury during the paediatric, adolescent and young adult age range has been well-defined for many treatments. However, further research is needed to improve our understanding of the effects of ageing on the health of adults who are treated for cancer during childhood (FIG. 4) Psychosocial and quality-of-life outcomes Long-term survivors of childhood and adolescent cancers are at risk of experiencing various psychological and social outcomes 19, [103] [104] [105] , which may result in decreased overall quality of life. Studies of long-term survivors have investigated the prevalence of and risk factors associated with educational and occupational attainment [106] [107] [108] [109] , access to health insurance 110, 111 , probability of marriage [112] [113] [114] , depression, anxiety and somatic distress [115] [116] [117] , post-traumatic distress 118, 119 , post-traumatic growth 120 , fatigue [121] [122] [123] and pain 124 . To varying degrees, the study of cancer-and treatment-related factors has identified high-risk populations. However, only limited data are available that describe longitudinal changes, and predictors of change, for the psychosocial functioning of ageing survivors of childhood and adolescent cancer 115, 118 .
Chronic health conditions, psychosocial sequelae and chronic symptoms may ultimately reduce the quality of survival through their effect on health and functional status [7] [8] [9] [10] [11] . These outcomes can be substantially influenced by the developmental age at the time of treatment, the presence of co-morbid conditions that precede cancer diagnosis, and the survivor's access to remedial and preventive services. For example, although younger paediatric patients have higher risks of neurocognitive injury after central nervous systemdirected therapy 61 , adolescent and young adult cancer survivors have been identified as a group that is particularly vulnerable to adverse psychosocial outcomes 11, 125 . To optimize health outcomes across the age range of childhood cancer survivors, care providers should consider the effects of both medical and psychosocial sequelae on the general health, mental health and function that is appropriate for the developmental age of the survivor, and they should help to facilitate survivors' access to remedial services.
Methodological and practical issues
A cancer survivor can be defined in various ways, which range from when the diagnosis is made to some post-diagnosis time point. From a vital statistics perspective, a cancer patient is considered to be a 'survivor' starting at diagnosis, whereas researchers often use a 'time from diagnosis' definition, which might be selected on the basis of the specific research question that is being addressed; for example, large cohorts, such as the Childhood Cancer Survivor Study 126 and the British Childhood Cancer Survivor Study 127 , have used 5 years from diagnosis, others have used 3 years post-diagnosis 128 , and some, such as the Bone Marrow Transplant Survivor Cohort, have applied alternative criteria using survival of ≥2 years from the time of haemato poietic stem cell transplant 10 . The major implication of differing definitions directly relates to the generalizability of the results and conclusions that are obtained from a specific population. Thus, as the amount of literature increases, it is important to consider how the source population was defined when describing the status and risk profiles for childhood cancer survivors. Beyond the definition of a cancer survivor, there are several research-related issues that need to be considered when interpreting the cancer survivorship literature, as these can all influence how results are interpreted and translated into clinical practice: the study design, source and eligibility criteria for the study population; the study sample size; participation rates; completeness of follow-up; how treatment-related exposures were assigned; ascertainment and characterization of outcomes; and the ability to consider potential modifiers of risk 129, 130 . The implementation of research in ageing survivor populations poses considerable challenges for researchers who must explain outcomes years after the discharge of patients from paediatric cancer treatment centres. Although challenging, crucial insights into the occurrence of and risk factors for longterm adverse outcomes have been achieved through clinical and epidemiological investigations, which have been carried out at various research venues. Without exception, any observational study of long-term outcomes of childhood cancer survivors has inherent limitations that affect the interpretation and the comparability of the research findings. Nonetheless, the replication of findings across various study populations, which are subject to different study methodologies and designs, is indicative of a powerful scientific approach to establishing and quantifying risk.
National registries and similar administrative sources can provide meaningful information about causes of mortality after childhood cancer, about health care use and about medical events such as subsequent neoplasms and pregnancy outcomes, but the linkage of outcomes to patient-specific data, especially the types and the doses of cancer treatment modalities, is required to identify groups who are at high risk for morbidity. Several large-cohort studies have successfully used survivor (or carer) reports of biomedical and psychosocial outcomes to describe longterm survivor health 126, 127 , but these studies are limited by the potential for survivors to misinterpret health events and the potential bias introduced by their variable access to health care and to screening for treatmentrelated toxicities. Ongoing cohort studies aim to more accurately characterize the health of long-term childhood cancer survivors through systematic medical assessments that are based on established cancer treatmentrelated toxicity profiles 131, 132 . The St. Jude Lifetime Cohort study identified a high prevalence of undiagnosed disease among 1,713 adult (median age: 32 years; age range: 18-60 years) survivors of childhood cancer (median time from diagnosis: 25 years; range: 10-47 years) who completed comprehensive outpatient risk-based medical testing during a 2-3-day period 8 . In this cohort, the estimated cumulative prevalence of survivors who would develop at least one chronic health condition by 45 years of age was 95.5%, and that of survivors who would develop a serious or disabling or life-threatening chronic condition by 45 years of age was 80.5% 8 . From this study, and other studies that report results from systematic health screening of adult survivors of childhood cancer, it is concerning that there are high prevalences of health conditions typically observed in much older individuals, such as neurocognitive and neuro sensory deficits, cardiovascular disease and pulmonary dysfunction 8, 133, 134 . These data suggest accelerated or premature ageing as a consequence of specific cytotoxic therapies that are used to cure childhood cancer, and this deserves further study. Although there is compelling evidence for the contribution of cancer treatment to organ dysfunction that presents during childhood, other factors, including co-morbid health problems, health habits and natural organ senescence, certainly modify the risk in ageing adults. Research to identify treatment, psychosocial and behavioural, genetic and demographic predictors of adverse outcomes is crucial to guide the screening and surveillance of survivors as they age, and it is crucial for the development of interventions to preserve the health of survivors.
Translation of outcomes-based research
The ideal approach to childhood cancer survivor care involves a risk-based model that incorporates routine health care and a personalized plan of surveillance and screening, as well as the management and prevention of late effects that are predisposed by cancer and its treatment 95 . Health outcomes research among childhood cancer survivors has yielded compelling data linking adverse outcomes with specific treatment modalities, and these data permit clinicians to identify potentially at-risk survivors. Several groups have used this evidence to inform clinical practice guidelines that aim to facilitate the early detection of cancer-treatment morbidity and the access of survivors to preventive and remedial interventions that can preserve health [135] [136] [137] [138] . A hybrid approach featuring an evidence-and consensus-based design has been used to develop guidelines that are related to the long-term follow-up care of childhood cancer survivors [135] [136] [137] [138] . This approach has been considered reasonable because of the strength of the evidence used to support numerous cancer treatmentrelated adverse outcomes and because of the crucial need for a resource for clinicians who manage the care of medically vulnerable survivors. Because paediatric cancer survivors are fairly rare in primary care practices, most community providers lack knowledge about the complications that may arise as a result of treatment for paediatric malignancies, and this may lead to their discomfort in supervising the care of survivors 139 -a problem that is made worse because many survivors and their families may also lack this knowledge. Currently available clinical practice guidelines provide information about the potential risks of late effects that are associated with specific cancer treatment modalities, targeted health screening, suggested methods of risk reduction and educational resources to assist providers in coordinating risk-based survivor care [135] [136] [137] [138] . It should be noted that optimal healthscreening after treatment for childhood, adolescent and young adult cancers has not yet been defined. Although published research on the risks of late effects provides insights into who may potentially benefit from screening and early detection after specific treatments, further research is required to determine when to initiate screening, the frequency of screening, the most efficacious and cost-effective modality of screening, and the overall risks, benefits and harms to the health care system and the survivor. The implementation of high-quality clinical studies assessing the effect of screening on the morbidity and the mortality that are associated with specific late effects is often precluded by the relatively small size of the paediatric cancer survivor population (represented by heterogeneous histological subtypes and treatment approaches), the diverse health risks that are associated with these treatments, and the frequency and delayed time to onset of many treatment complications. Notwithstanding these limitations, in addition to standardizing follow-up care to respond to the unique health care needs of childhood cancer survivors, the currently available clinical practice guidelines provide an important platform for research to begin to address knowledge gaps in the care of childhood cancer survivors. In this regard, recently published research has focused on evaluating the benefit of specific diagnostic studies in identifying late effects 8, 134, 140, 141 . Pertinent considerations in interpreting the results of these studies include variability in the age of the cancer patients at the time of treatment, age at the time of screening, time from cancer treatment and representativeness to source population. Collectively, these studies show that screening identifies a substantial proportion of childhood cancer survivors who have previously unrecognized, treatment-related health complications of varying degrees of severity. Specifically, riskbased screening among participants in the St. Jude Lifetime Cohort identified a high prevalence of newly discovered neurocognitive and neurosensory deficits, heart valve disorders and pulmonary dysfunction that may benefit from remedial and preventive interventions to reduce future declines in function 8 . Until recently, national groups have worked independently to develop clinical practice guidelines, and this has resulted in a variation in screening recommendations, patient risk groups, diagnostic tests and screening intervals [135] [136] [137] [138] . Recognizing the inefficient use of resources that has resulted from this non-integrated approach to guideline development, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) was formed in 2010 with the goal of establishing a common vision and an integrated strategy for the surveillance of late effects in childhood, adolescent and young adult cancer survivors throughout the world 142 . This collaboration will provide a unique forum to address knowledge gaps related to the care of cancer survivors, and it will provide methods to optimize the implementation of clinical practice guidelines and their effect on the quality of care given to childhood cancer survivors.
Beyond the translation of research-based knowledge into clinical care guidelines, it is now important to focus greater attention on translating knowledge from research to the development and the testing of interventionbased approaches, which are designed to avoid or ameliorate adverse outcomes. It is hoped and expected that the future portfolio of intervention-based research will encompass a wide range of approaches and outcomes. Specific interventions may include social, behavioural and/or pharmacological approaches. Owing to the often multifactorial nature of known or anticipated risk factors for the majority of adverse outcomes (such as cardiotoxic therapy, obesity, tobacco use and risk for cardiac disease), interventions might be most effective when they use a combination of approaches. Outcomes for intervention research may relate to changes in health behaviours such as diet, exercise and tobacco use; health care practices such as ongoing medical surveillance and compliance with recommended risk-based screening; prevention or amelioration of adverse health outcomes such as cancer, congestive heart failure, obesity, fatigue or hypertension; and promotion of positive social and quality-of-life outcomes such as education, employment, access to health insurance and mental health.
Future challenges
With the rapid increase in evidence regarding the health risks associated with survival after successful treatment of paediatric or adolescent cancer, medical and research communities have the ongoing responsibility to critically evaluate the literature, define the characteristics of populations at high risk for morbidity and translate this evidence to clinical practice guidelines for riskstratified follow-up care. The implementation and dissemination of outcomes and of intervention-based research must consider potential barriers that occur at the level of the survivor, the health care provider or the health care environment, which affect the access of survivors to quality care (FIG. 3) .
Survivor-related barriers.
A lack of knowledge regarding cancer treatment history and its associated long-term health risks [143] [144] [145] is an important barrier to the participation of survivors in follow-up care. Paediatric late effects programmes have aimed to remediate this through longitudinal health counselling and the provision of treatment summaries and survivorship care plans 146 . The educational process is complicated by the fact that the transition of care typically occurs when survivors reach a developmental age at which they may be more aware of cancer-related health risks and personally responsible for health behaviours. The published research that relates to these initiatives is mostly limited to descriptive studies of clinic-based interventions 21, 147, 148 . Few studies assess the effect of clinic-based interventions on survivor health knowledge, health perceptions or health behaviours, including their ongoing participation in care 143, 149, 150 . Despite the absence of evidence to support specific benefits from the counselling and the resources that are routinely provided in late effects programmes, the consensus remains that such interventions represent good clinical care 151 . However, there is a crucial need for future research to define effective and efficient methods of health risk counselling that is developmentally and culturally appropriate for the survivor population.
Provider-related barriers. Knowledge deficits among health care providers regarding health issues that affect paediatric cancer survivors can also pose barriers to the delivery of good survivorship care. Surprisingly, a lack of familiarity with the recommended screening for paediatric cancer treatment toxicities is not limited to primary care providers. In a study that evaluated preferences and knowledge gaps among paediatric oncologists regarding the care of childhood cancer survivors, only 33% of respondents correctly answered vignette-based questions about the surveillance recommendations for breast cancer, cardiomyopathy and thyroid function 152 . These providers expressed increasing discomfort in managing the care of paediatric survivors who were ≥21 years of age, but a significant proportion (38%) preferred to observe their survivors for as long as possible. In a related study that evaluated the same outcomes among family physicians, only 2% of respondents correctly answered the same vignette-based questions . The vast majority (85%) of these family physicians preferred to care for survivors in consultation with clinicians from a cancer treatment centre or a late effects programme. Access to clinical care guidelines and the receipt of a patientspecific letter detailing surveillance recommendations were perceived by the physicians to be the modalities that were most likely to assist them in survivorship care. These interventions were successfully implemented in a model of shared care between Dutch paediatric oncologists and family doctors 153 . These studies highlight the need to increase the amount of education and training programmes related to survivorship care for health professionals, improve the dissemination of clinical practice guidelines for treating survivors of childhood cancer, and evaluate methods to increase communication and collaboration among the oncology and primary care providers who share survivorship care.
Barriers related to the health care environment. Potential barriers to good care of cancer survivors that are imposed by the health care environment relate to the availability of providers and survivorship resources, specialized late effects clinics and operational models of survivorship care, which are greatly influenced by provider and payer relationships and by health care policies. In the United States, care given to cancer survivors is generally a non-revenue-generating service for providers because of limited or absent reimbursement for substantial components of the care 154 . This reality represents a considerable threat to the access of survivors to specialized late effects clinics that have multidisciplinary staff with expertise in late effects, health screening and surveillance. These programmes also focus on educating survivors, on promoting the access of survivors to resources that remediate or prevent treatment-related toxicities, and on facilitating communication and care transitions with community providers. The care of most paediatric cancer survivors is eventually passed to community providers because specialized paediatric late effects programmes are not universally available, and when they are available they usually have institutional age limitations that preclude follow-up beyond adolescence 155 . This transition of care can be complicated by suboptimal communication among members of the treating oncology team and primary care providers who lack awareness about the unique health risks associated with the treatment of cancer during childhood and with screening and surveillance recommendations. Various models of survivorship care have been implemented to facilitate care transitions and to ensure that the health care needs of childhood cancer survivors are optimally addressed 156 . Among these, a shared-care model that uses a risk-stratified approach based on treatment intensity, or risk for late effects, has been favoured by late effects specialists because this model promotes ongoing communication across the range of cancer care and takes advantage of the expertise of the oncology team and the primary care provider during delivery of care 156 . Research is required to delineate the essential elements of survivorship care and flexible models of care delivery that can increase the access of survivors to interventions that proactively address cancer-related morbidity.
Insurance and policy barriers. In countries such as the United States, where governmentbased health care is not provided, lack of health insurance or health policy exclusions and restrictions represent a considerable barrier to the care of cancer survivors, which may disproportionately affect individuals who have a racial or ethnic minority status or a low socioeconomic status. National health legislation such as the US Patient Protection and Affordability Act provides many policy changes to ensure that paediatric cancer survivors have access to appropriate health care services 157 . This legislation provides mechanisms to increase the level of access to components of survivorship care, but additional measures will be required to achieve the goal of high quality, comprehensive and coordinated survivorship care. To realize this goal, health care policy change is needed to define the essential metrics of quality care that should be accessible to all survivors, and it is needed to improve provider reimbursement for comprehensive-care coordination that includes assessment for medical and psychosocial sequelae, delivery of interventions to remediate or prevent treatment complications, counselling regarding methods of risk reduction, and referral to resources that help to address medical, psychosocial and practical needs.
Conclusions
Although the many individuals who have had a role in achieving the remarkable increase in the survival rates of childhood and adolescent cancers should be gratified, with success also comes responsibility. Simply focusing on the cure of the cancer cannot be an acceptable objective when considering the life-long risk of developing treatment-related complications that survivors experience. Because of the young age of these cancer survivors, and thus their potential longevity, the delayed consequences of therapy will probably have a greater effect on their lives, their families and on society at-large, than the acute complication of the cytotoxic and surgical therapies that they have already experienced. Thus, there is a role not only for researchers and health care providers but also for survivors and their families, governing bodies and advocacy groups in helping to understand and overcome the barriers that prevent survivors from receiving optimal care to minimize adverse health-related outcomes and to maximize quality-of-life outcomes. 
